This site is intended for US Healthcare Professionals only.
neffy® (epinephrine nasal spray) logo
  • About neffy
    • Why neffy?
    • How neffy works
  • Clinical trial results
    • PD data
    • Oral food challenge
    • PK data
    • Safety data
  • Dosing and usage
  • Resources
    • Accessing neffy
    • Demonstration device program
    • Resource library
    • Co-pay card
  • Importance of epinephrine use
  • Request Support

Request support

STAY INFORMED AND CONNECTED

Learn more about neffy—for your patients with type I allergic reactions

Request information by checking the appropriate box[es] below:

Please select at least one checkbox below.
*Required fields.
Please enter your first name.
Please enter your last name.
Please enter a valid email address.
phone number is invalid
SELECT AN OPTION
  • Healthcare Professional
  • School Nurse
  • Other
Please select an option.
Please enter your NPI number.
Please enter your address.
Please enter your city.
SELECT AN OPTION
  • Alabama
  • Alaska
  • Arizona
  • Arkansas
  • California
  • Colorado
  • Connecticut
  • Delaware
  • District of Columbia
  • Florida
  • Georgia
  • Hawaii
  • Idaho
  • Illinois
  • Indiana
  • Iowa
  • Kansas
  • Kentucky
  • Louisiana
  • Maine
  • Maryland
  • Massachusetts
  • Michigan
  • Minnesota
  • Mississippi
  • Missouri
  • Montana
  • Nebraska
  • Nevada
  • New Hampshire
  • New Jersey
  • New Mexico
  • New York
  • North Carolina
  • North Dakota
  • Ohio
  • Oklahoma
  • Oregon
  • Pennsylvania
  • Puerto Rico
  • Rhode Island
  • South Carolina
  • South Dakota
  • Tennessee
  • Texas
  • Utah
  • Vermont
  • Virginia
  • Washington
  • West Virginia
  • Wisconsin
  • Wyoming
Please select a state.
Please enter a ZIP code.
This field is required.
Gradient
  • PREVIOUS

IMPORTANT SAFETY INFORMATION & INDICATION

+

IMPORTANT SAFETY INFORMATION

It is recommended that patients are prescribed and have immediate access to two neffy nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of neffy in the same nostril with a new nasal spray starting 5 minutes after the first dose.

INDICATION

neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients aged 4 years and older who weigh 15 kg or greater.

neffy is for use in the nose only.

Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.

Absorption of neffy may be affected by underlying structural or anatomical nasal conditions.

Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

The presence of a sulfite in neffy should not deter use.

neffy may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including neffy.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions.

Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson’s disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women.

Most common adverse reactions are nasal discomfort, headache, rhinorrhea, dizziness, nausea, vomiting, throat irritation, nasal congestion, paresthesia, sneezing, upper respiratory tract congestion, epistaxis, rhinalgia, nasal dryness, dry throat, fatigue, and feeling jittery.

These are not all of the possible side effects of neffy. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for neffy.

  • LinkedIn logo
  • Twitter logo
  • Privacy Policy
  • Contact
  • Site Map
  • Information for Colorado Prescribers
  • Information for Connecticut Prescribers
ARS Pharmaceuticals logo

©2025 ARS Pharmaceuticals Operations, Inc.  All rights reserved.  “ARS Pharma,” the ARS Pharma logo design, “neffy,” the neffy logo, and the neffyconnect logo are trademarks or registered trademarks of ARS Pharmaceuticals Operations, Inc.
All other trademarks are the property of their respective owners. NEF-US-0088-1 | 05/2025